IBI-3019

N/A

Report date: 2025/06/04 14:33:19
First In Class

Base Information

Drug NameIBI-3019
Drug Alias NameIBI3019IBI-3019
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody
Mechanisms of ActionAnti-Epidermal growth factor receptor erbB1Anti-Cadherin-17Anti-Low affinity immunoglobulin gamma Fc region receptor III-A
TargetsEpidermal growth factor receptor erbB1Cadherin-17Low affinity immunoglobulin gamma Fc region receptor III-A
Therapy Area/IndicationsColorectal NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesInnovent Biologics Inc
China Registration ClassN/A

Develop Information

Active CompaniesInnovent Biologics Inc
Inactive CompaniesInnovent Biologics Technology Ltd
Active IndicationsColorectal Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A